A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study

American Journal of Medicine

Volumn 109, Issue 4, 2000, Pages 267-276

  Chesnut III, Charles H ^a   Silverman, Stuart ^b   Andriano, Kim ^c   Genant, Harry ^d   Gimona, Alberto ^c   Harris, Steven ^d   Kiel, Douglas ^e   Leboff, Meryl ^f   Maricic, Michael ^g   Miller, Paul ^h   Moniz, Caje ⁱ   Peacock, Munro ^j   Richardson, Peter ^c   Watts, Nelson ^k   Baylink, David ^l  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RHODE ISLAND HOSPITAL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF ARIZONA   (United States)

^h University of Colorado Health Sciences Center   (United States)

ⁱ KING S COLLEGE HOSPITAL   (United Kingdom)

^j INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^k EMORY CLINIC   (United States)

^l Jerry L Pettis Memorial VA Medical Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM CARBONATE; CENTRUM; COLLAGEN TYPE 1; NOSE SPRAY; OSTEOCALCIN; PEPTIDE; PLACEBO; SALCATONIN; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NOSE CONGESTION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RHINITIS; SNEEZING; SPINE RADIOGRAPHY; VERTEBRA FRACTURE;

AGED; ANALYSIS OF VARIANCE; BONE DENSITY; CALCITONIN; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MIDDLE AGED; NASAL CAVITY; OSTEOPOROSIS, POSTMENOPAUSAL; RECURRENCE; REFERENCE VALUES; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 0033829969     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00490-3     Document Type: Article

References (53)

1. Azria M. The Calcitonins Physiology and Pharmacology . 1989;Karger, New York.
2. Baron B., Vignery A. Behavior of osteoclasts during a rapid change in their number induced by high doses of parathyroid hormone or calcitonin in intact rats. Metab Bone Dis Relat Res. 2:1981;339-346.
3. Kallio D.M., Garant P.R., Minkin C. Ultrastructural effects of calcitonin on osteoclasts in tissue culture. J Ultrastruct Res. 39:1972;205-216.
4. Holtrop M.E., Raisz L.G., Simmons H.A. The effects of parathyroid hormone, colchicine, and calcitonin on the ultrastructure and the activity of osteoclasts in organ culture. J Cell Biol. 60:1974;346-355.
5. Raisz L.G. Bone metabolism and its hormonal regulation. Triangle. 22:1983;83-84.
6. Chambers T.J., Azria M. The effect of calcitonin on the osteoclast. Triangle. 27:1988;53-60.
7. Ellerington M.C., Hillard T.C., Whitcroft S.I., et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int. 59:1996;6-11.
8. Kapetanos G., Symeonides P.P., Dimitriou C., et al. A double blind study of intranasal calcitonin for established postmenopausal osteoporosis. Acta Orthop Scand Suppl. 275:1997;108-111.
9. Overgaard K., Riis B.J., Christiansen C., et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf). 30:1989;435-442.
10. Overgaard K., Riis B.J., Christiansen C., Hansen M.A. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ. 299:1989;477-479.
11. Overgaard K., Hansen M.A., Nielsen V.A., et al. Discontinuous calcitonin treatment of established osteoporosis - effects of withdrawal of treatment. Am J Med. 89:1990;1-6.
12. Overgaard K., Christiansen C. Long-term treatment of established osteoporosis with intranasal calcitonin. Calcif Tissue Int. 49:1991;S60-S63.
13. Overgaard K., Hansen M.A., Jensen S.B., Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis a dose-response study . BMJ. 305:1992;556-561.
14. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women a dose-response study . Calcif Tissue Int. 55:1994;82-86.
15. Reginster J.Y., Denis D., Albert A., et al. 1-Year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet. 2:1987;1481-1483.
16. Reginster J.Y., Denis D., Deroisy R., et al. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res. 9:1994;69-73.
17. Reginster J.Y., Meurmans L., Deroisy R., et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin, and calcium. Eur J Clin Invest. 24:1994;565-569.
18. Reginster J.Y., Deroisy R., Lecart M.P., et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med. 98:1995;452-458.
19. Thamsborg G., Jensen J.E., Kollerup G., et al. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone. 18:1996;207-212.
20. Rico H., Revilla M., Hernandez E.R., et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin a prospective study . Calcif Tissue Int. 56:1995;181-185.
21. Gruber H.E., Ivey J.L., Baylink D.J., et al. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism. 33:1984;295-303.
22. Wallach S., Farley J.R., Baylink D.J., Brenner-Gati L. Effects of calcitonin on bone quality and osteoblastic function. Calcif Tissue Int. 52:1993;335-339.
23. Mosekilde L., Danielsen C.C., Gasser J. The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats. Endocrinology. 134:1994;2126-2134.
24. Geusens P., Boonen S., Nijs J., et al. Effect of salmon calcitonin on femoral bone quality in adult ovariectomized ewes. Calcif Tissue Int. 59:1996;315-320.
25. Karachalios T., Lyritis G.P., Giannarakos D.G., et al. Calcitonin effects on rabbit bone. Bending tests on ulnar osteotomies. Acta Orthop Scand. 63:1992;615-618.
26. Burnell J.M., Baylink D.J., Chesnut C.H., Teubner E.J. The role of skeletal calcium deficiency in postmenopausal osteoporosis. Calcif Tissue Int. 38:1986;187-192.
27. Kanis J.A., Johnell O., Gullberg B., et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ. 305:1992;1124-1128.
28. Wu C.Y., Li J., Jergas M., Genant H.K. Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures. Osteoporosis Int. 5:1995;354-370.
29. Genant H.K., Jergas M., Palermo L., et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res. 11:1996;984-996.
30. Lu Y., Mathur A.K., Blunt B.A., et al. Dual x-ray absorptiometry quality control. comparison of visual examination and process-control charts. J Bone Miner Res. 11:1996;626-637.
31. Lu Y., Ye K., Mathur A.K., et al. Comparative calibration without a gold standard. Stat Med. 16:1997;1889-1905.
32. Farley J.R., Hall S.L., Ilacas D., et al. Quantification of skeletal alkaline phosphatase in osteoporotic serum by wheat germ agglutinin precipitation, heat inactivation, and a two-site immunoradiometric assay. Clin Chem. 40:1994;1749-1756.
33. Garnero P., Grimaux M., Demiaux B., et al. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res. 7:1992;1389-1398.
34. Gundberg C.M. Biology, physiology, and clinical chemistry of osteocalcin. J Clin Ligand Assay. 21:1998;128-138.
35. Singer F.R., Aldred F.P., Neer R.M., et al. An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest. 51:1972;2331-2338.
36. Cox D.R. Regression models and life-tables. J Royal Stat Soc (Series B). 34:1972;187-220.
37. Littell R, Milliken G. SAS system for mixed models. Cary, North Carolina: SAS Institute, 1996:633.
38. Takahashi S., Goldring S., Katz M., et al. Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest. 95:1995;167-171.
39. Levy F., Muff R., Dotti-Sigrist S., et al. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. J Clin Endocrinol Metab. 67:1988;541-545.
40. Muff R., Dambacher M.A., Fischer J.A. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis. Osteoporosis Int. 1:1991;72-75.
41. Grauer A., Raue F., Schneider H.G., et al. In vitro detection of neutralizing antibodies after treatment of Paget's disease of bone with nasal salmon calcitonin. J Bone Miner Res. 5:1990;387-391.
42. Riggs B.L., Melton L.J. III, O'Fallon W.M. Drug therapy for vertebral fractures in osteoporosis evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy . Bone. 18:1996;197S-201S.
43. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med. 103:1997;12S-19S.
44. Black D.M., Cummings S.R., Karpf D.B., et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 348:1996;1535-1541.
45. Ensrud K., Black D., Recker R., et al. The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. Bone. 23:(suppl 5):1998;S174.
46. Kraenzlin M.E., Seibel M.J., Trechsel U., et al. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers evidence of maximal effect after 8 weeks of continuous treatment . Calcif Tissue Int. 58:1996;216-220.
47. Chesnut C.H. III, McClung M.R., Ensrud K.E., et al. Alendronate treatment of the postmenopausal osteoporotic woman effect of multiple dosages on bone mass and bone remodeling . Am J Med. 99:1995;144-152.
48. Garnero P., Shih W.J., Gineyts E., et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 79:1994;1693-1700.
49. Liberman U.A., Weiss S.R., Bröll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 333:1995;1437-1443.
50. Dempster D.W. Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis. J Bone Miner Res. 12:1997;1152-1154.
51. Garnero P., Hausherr E., Chapuy M.C., et al. Markers of bone resorption predict hip fracture in elderly women the EPIDOS Prospective Study . J Bone Miner Res. 11:1996;1531-1538.
52. Cummings SR, Black DM, Vogt TM, for the FIT Research Group. Changes in BMD substantially underestimate the anti-fracture effects of alendronate, and other antiresorptive drugs. J Bone Miner Res. 1996;11:(suppl 1) S102:29.
53. Chavassieux P.M., Arlot M.E., Reda C., et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 100:1997;1475-1480.